Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Donya Marandi

Nurse Practitioner Nashville, TN Nurse Practitioner

NPI 1083353262 CMS profile 11350263

330 22Nd Ave N, Nashville, TN 37203

Open in the dashboard

General payments

$843

45 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donya Marandi of Nashville, TN is reported in the CMS Open Payments database as having received $843 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $606 30
2024 General $224 14
2023 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donya Marandi
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Donya Marandi were reported at $606. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Donya Marandi Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $13 $166 $54–$529 $160
2024 $224 $173 $55–$556 $164
2025 $606 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Boston Scientific Corporation $237 15 payments
  2. Collegium Pharmaceutical, Inc. $147 7 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $109 6 payments
  4. Averitas Pharma Inc. $79 3 payments
  5. Vertex Pharmaceuticals Incorporated $67 4 payments
  6. IBSA Pharma Inc. $48 2 payments
  7. Axsome Therapeutics, Inc. $44 2 payments
  8. Merz Pharmaceuticals, LLC $36 2 payments
  9. Pfizer Inc. $32 2 payments
  10. AbbVie, Inc. $23 1 payment
  11. Other $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $843 45 payments
Products named General payments · program years 2023–2025
  1. WaveWriter Alpha Prime 16 $146 9 payments
  2. BELBUCA $129 6 payments
  3. RELISTOR $109 6 payments
  4. Qutenza $79 3 payments
  5. JOURNAVX $67 4 payments
  6. Tirosint $48 2 payments
  7. Licart $48 2 payments
  8. Flector $48 2 payments
  9. Symbravo $44 2 payments
  10. Xeomin $36 2 payments
  11. Other $148 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

556

Median for Nurse Practitioner: 389

Drug cost

$5,516

Median for Nurse Practitioner: $21,885

Branded share of claims

60.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 133 $2,320
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 84 $552
Methocarbamol Generic 41 $426
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 93 $402
Lidocaine Generic 13 $331
Cyclobenzaprine Hcl Generic 33 $232
Methylprednisolone Generic 29 $229
Dicloxacillin Sodium Generic 15 $221
Silver Sulfadiazine Generic 20 $172
Tizanidine Hcl Generic 30 $170

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record